Friday 6 November 2026 Export DNLI’s income statement to Excel — free account

Denali Therapeutics Inc.

Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.

Revenue: −94.0%
EPS: +150.3%
Free cash flow: −11.8%
Total debt: −1.89%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

20.31 0.59 +2.99%

Follow DNLI

Alert me

Market cap: $3.2B
P/E: 0.0×
Fwd P/E: −7.7×
Dividend yield: —
F-score: 4/9
Altman Z: 13.78
Beneish M: n/a
Dividend safety: n/a

Overview

Denali Therapeutics Inc. (DNLI) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Denali Therapeutics Inc. (DNLI) trades at a P/S ratio of 165×. Over the past ten years it has ranged from 0.0× (December 2018) to 428× (December 2020); the current reading is higher than 97% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/DNLI/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Denali Therapeutics Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/DNLI/metrics/ps-ratio">Denali Therapeutics Inc. (DNLI) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2023	8.9×	(72.20%)
FY2022	32.0×	(71.29%)
FY2021	111×	309.60%
FY2020	27.2×	(56.44%)
FY2019	62.4×	321.38%
FY2018	14.8×	—

Period	P/S ratio	Change
Sep 2026	172×	967.00%
Jun 2026	16.1×	81.25%
Dec 2023	8.9×	11.23%
Sep 2023	8.0×	(32.19%)
22 more quarters	Free account

Against its own ten years

Low 0.0× High 428×

Ten-year median 13.9×

Current reading's percentile 97

Company	P/S ratio
VKTX Viking Therapeutics, Inc. compare	n/m
CELC Celcuity, Inc. compare	n/m
DYN Dyne Therapeutics, Inc. compare	n/m
ELVN Enliven Therapeutics, Inc. compare	n/m
TARS Tarsus Pharmaceuticals, Inc. compare	4.6×
IDYA IDEAYA Biosciences, Inc. compare	86.7×
VRDN Viridian Therapeutics, Inc. compare	118×
DNLI Denali Therapeutics Inc.	165×
TLX Telix Pharmaceuticals Limited compare	—
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Denali Therapeutics Inc. (DNLI) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on DNLI

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on DNLI

Stockrow Weekly